Ticker: SCD (LMP Capital and Income Fund Inc.) – Note: Despite the ticker, SCD here refers to a closed-end fund, not directly to Sickle Cell Disease (the context of new data at the ASH meeting). LMP Capital and Income Fund Inc. is a diversified closed-end investment fund focused on total return (with an emphasis on income) via a broad mix of equity and fixed-income investments ([1]). Below we delve into its dividend policy, leverage, valuation, and key risk factors, grounding our analysis in official filings and credible sources.
Dividend Policy, History & Yield
Managed Distribution: SCD employs a managed distribution policy, paying a fixed monthly dividend irrespective of short-term income fluctuations ([2]). Currently, the fund distributes $0.12 per share each month, which annualizes to $1.44 per share ([3]) ([2]). This has resulted in a yield of ~9.7% on the market price (as of late November 2025) ([3]). The distribution rate on the fund’s NAV is slightly lower (~8.7%-8.8%) due to the fund trading at a discount (discussed below) ([3]) ([2]).
Historical Stability: The fund’s payout has been relatively consistent, though not immune to adjustments. In recent years, SCD’s monthly dividend was trimmed during the mid-2010s and early 2020s amid market stress, then raised again in 2023. For example, the fund paid about $1.04/year during fiscal 2021–2022, then increased to $1.35/year in 2023, corresponding to a hike in the monthly rate from roughly $0.087 to $0.113 ([4]). The current $0.12 monthly rate (initiated in late 2024) reflects that boost ([3]) ([4]). Management’s willingness to adjust the payout suggests a focus on sustainability over time.
Income vs. Return of Capital: Importantly, SCD’s dividends are not fully covered by net investment income (NII). The fund emphasizes total return – meaning it distributes not just earnings (interest/dividends received minus expenses) but also realized capital gains, and if needed, return of capital. In the latest reporting period, only about 10% of distribution came from NII, while ~90% was sourced from realized capital gains ([4]). In prior years, when capital gains were scarce, a portion of the payout was classified as return of capital (ROC) to shareholders ([4]). The fund explicitly states it will even pass through cash received from its MLP and REIT holdings even if that cash represents return of capital at the fund level ([4]). This policy can support a high payout, but it means investors should monitor the composition of distributions. A large ROC component effectively pays investors back with their own principal, eroding NAV over time if not offset by future gains. (Notably, year-to-date fiscal 2024 distributions had no ROC because robust realized gains funded the payout ([5]), but prior years did include ROC.) Management sends Section 19(a) notices for transparency on distribution sources ([5]).
Dividend Coverage: Given the above, coverage of the dividend by earnings is low. For the half-year ended May 31, 2024, SCD generated NII of ~$2.37 million versus distributions of roughly ~$11.6 million in that period (estimation based on shares and $0.113 monthly rate), implying NII covered only ~20% of the payout ([4]). The remainder was covered by $15.3M in net realized gains that the fund harvested from its portfolio ([4]). In other words, SCD relies on successful portfolio appreciation (or, if necessary, a bit of NAV giveback) to maintain its high yield. Investors should consider that the current ~9-10% yield is supported largely by capital gains and not by ordinary income alone ([4]). This is common for multi-asset closed-end funds with managed distributions, but it introduces risk if market conditions turn adverse (as discussed under Risks).
Leverage and Debt Profile
Leverage Utilization: SCD employs leverage to enhance returns and income, a typical strategy for closed-end funds. As of mid-2024, the fund had about $67 million in borrowings outstanding under a credit facility ([4]). This represented roughly 20–25% of total assets (given net assets around $250–300M pre-rights-offering) – a moderate leverage ratio in line with peers. The credit facility is a margin loan agreement with Bank of America that allows borrowing up to $80 million, renewing on a rolling 179-day term ([4]). The interest is floating (tied to SOFR + a margin) and thus has increased with rising rates. For the six months ended May 31, 2024, SCD’s average borrowing rate was 6.12%, and it incurred $2.06 million of interest expense in that half-year ([4]). Extrapolating, interest costs (~$4+ million annually) are a drag on NII, but are currently outweighed by the fund’s investment income and gains. The fund also pays a small commitment fee (0.07–0.10% on unused amounts) for access to the credit line ([4]).
Debt Maturities: SCD does not issue long-term bonds or debentures; instead, it finances leverage via short-term bank loans. The loan is effectively demand financing, renewably short-term, which gives flexibility but also means exposure to interest rate resets and lender risk. There is no set maturity date to stagger, but investors should note the credit agreement can be terminated or called under certain conditions ([4]). The lender imposes covenants, including asset coverage requirements and limits on additional debt or distributions if assets fall too much ([4]). In essence, if the portfolio value drops significantly, SCD might be restricted from paying dividends or forced to de-lever to maintain the 1940 Act minimum 300% asset coverage ratio. As of May 2024, asset coverage was comfortable, but this is a point of ongoing risk management.
Capital Structure Changes: In mid-2025, SCD took action to raise equity capital: it conducted a 1-for-3 rights offering that issued ~5.7 million new shares at $15.20 each, raising about $87 million in gross proceeds ([3]). This move (completed July 2025) expanded net assets by nearly 30% (net assets rose from ~$288M to ~$375M post-offering) ([3]). The offering was oversubscribed, indicating strong demand ([3]). However, issuing shares below NAV ($15.20 vs. a NAV in the mid-$16s at that time) introduced slight dilution to NAV per share. It also increased the share count, which can put near-term pressure on the market price (often, CEF rights offerings lead to a wider discount as the market digests additional supply). On the positive side, the infusion likely allowed SCD to reduce leverage (temporarily or deploy into new opportunities) – for example, some of the cash may have paid down part of the loan or been invested incrementally. The fund’s total net assets stood at $374.5 million by October 31, 2025 ([3]), and leverage remained available up to the $80M limit if needed. Going forward, the larger asset base could help with trading liquidity and potentially spread fixed costs, though it also increases management fees in absolute terms.
Leverage Impact: By policy, SCD can leverage via loans, preferred shares, or other instruments up to limits allowed (typically 33% of total assets for debt) ([6]). Leverage is a double-edged sword – boosting income and total return in good times, but magnifying losses in downturns. The fund explicitly acknowledges that with leverage, its NAV will be “more volatile and all other risks will tend to be compounded.” ([6]). Shareholders should be prepared for higher NAV and price fluctuations due to this borrowing. Also, rising interest rates squeeze the fund’s earnings: borrowing costs have roughly doubled in the past two years (from ~3% to ~6%+), while yields on some fixed-income holdings have lagged or credit assets may have depreciated – a margin pressure many leveraged funds face.
Coverage and Earnings Quality
NII and Coverage: As noted, Net Investment Income covers only a fraction of SCD’s distribution. In the latest fiscal half-year, NII was about $2.37M, far below the ~$11M paid in dividends ([4]). Full-year figures show a similar pattern; for instance, in fiscal 2023 (year ended Nov 30), NII was only ~$0.03 per share, whereas the fund paid $1.35 per share in distributions ([4]). The gap is filled by realized gains and occasionally return of capital. Practically, interest and dividends earned from the portfolio are not sufficient to fund the 9% payout – additional support comes from selling appreciated securities. This strategy can work so long as the fund consistently finds winners or markets rise, but it is not a traditional “covered” dividend in the way of an income-only strategy.
Earnings Composition: SCD’s portfolio is allocated roughly ~70% to equities (including some higher-dividend stocks and MLPs) and ~30% to fixed-income (including high-yield bonds) ([3]) ([3]). As a result, it does generate some cash income: interest from bonds and dividends from stocks/MLPs. However, after expenses (management fee of 0.85% of managed assets ([4]), interest on debt, etc.), the recurring income is much lower than the payout. For example, for the six months through May 2024, the fund’s investment income (net of expenses) was $2.37M ([4]), whereas it realized over $15M in capital gains by actively trading holdings ([4]). SCD’s distribution coverage therefore depends heavily on realized gains. In 2023’s strong market, this meant much of the dividend was funded by long-term capital gains (about 86% of YTD distributions through Aug 2024 came from realized long-term gains) ([5]). In weaker periods, the fund has opted to let distributions exceed total income and gains, classifying the shortfall as return of capital. For instance, in fiscal 2021–2022, roughly 50% or more of the dividends were ROC by year-end tax character ([4]). While return of capital in a given year isn’t inherently bad (it can be tax-efficient, and might simply reflect giving back some principal during a down market), persistent ROC can signal the payout is too high relative to what the fund earns.
Coverage Outlook: A key question is whether rising interest rates and equity dividends will improve NII coverage going forward. The fund’s fixed-income sleeve (managed by Western Asset) could earn higher yields on reinvestment now, and equity dividends have been growing in many cases. However, the cost of leverage has also increased, offsetting some of that potential income gain. At a ~6% borrowing cost, the spread between what SCD earns on investments and what it pays on debt narrows unless the fund rotates into higher-yielding assets (often with higher risk). Thus, it may be challenging for NII alone to ever cover a majority of the distribution if the rate stays at $0.12/month. Management’s stance, per policy, is to distribute all NII and whatever additional cash from MLP/REIT investments each month, and then supplement with gains/ROC as needed ([4]) ([4]). They have shown a commitment to the managed payout, so a cut would likely be a last resort only if long-term performance severely faltered. For now, distribution coverage rests on the fund’s ability to keep realizing gains – essentially harvesting winners to support the generous yield.
Valuation and Comparables
Market Price vs. NAV: SCD’s market price currently trades at a notable discount to its Net Asset Value. As of late November 2025, the share price was around $14.80 while NAV was about $16.37, a ~9.6% discount ([2]). This means investors can buy the fund’s $1 of assets for roughly $0.90 in the market. Such a discount is common in the closed-end fund universe, though the magnitude varies. SCD’s 12-month average discount was about 5.6%, so the current gap is wider than usual ([2]). In fact, over the past year the discount has ranged from about -11.3% (widest) to occasionally a slight premium of +3.8% at the peak ([2]). Thus, the current ~10% discount is near the wider end of its recent range, potentially offering value if one expects mean-reversion (i.e. the discount to narrow).
Reasons for Discount: Several factors might explain the widening discount. The mid-2025 rights offering likely put near-term pressure on the price – such offerings often cause price/NAV dislocations as new shares hit the market below NAV. Additionally, rising interest rates and market volatility in 2025 have generally put many leveraged funds at deeper discounts, as investors grow cautious of their prospects. SCD’s performance in 2025 has been slightly negative on NAV basis (the 1-year total return on NAV was about +4.8% as of Nov 28, 2025, below the distribution rate) ([2]), meaning the fund’s NAV hasn’t fully earned its payout over the last year. This can make investors skeptical of sustainability, contributing to a discount. Finally, general supply/demand technicals (the fund’s increased size and the fact that it’s one of many income CEFs available) play a role.
Peer Comparison: SCD falls into a “moderately aggressive allocation” category ([3]) – comparable to other multi-asset income-oriented CEFs. Many peers likewise trade at discounts, often in the mid-single digits to low teens, and yields in the 7–10% range. For example, as a rough comp, John Hancock Income & Opportunies Fund (JHI) or Calamos Strategic Total Return (CSQ) (not exact strategy matches but mixed-asset funds) trade at ~8–12% discounts with ~8–9% yields. SCD’s ~9–10% market yield is on the higher side, reflecting the fund’s use of equity and high-yield exposure for return enhancement. Its discount around 10% is also somewhat wider than a typical balanced fund’s discount in the mid-single digits (by contrast, some equity CEFs trade near NAV or even at premiums if demand is strong). We also note SCD’s NAV performance vs. benchmarks: over the last 5-10 years, it has modestly underperformed a blended 65% stock/35% bond index (for 10-year: 6.5% NAV return vs ~7.1% for benchmark) ([6]) ([6]). This could temper investor enthusiasm and help explain a persistent discount – essentially, the market may be demanding a margin of safety (discount) given the fund’s fee drag and episodic ROC usage.
Premium/Discount Dynamics: The fact that SCD occasionally traded near par or a small premium in the past year (up to +3.8%) ([2]) suggests that if sentiment improves, the discount can shrink. Catalysts for narrowing could include a period of strong NAV performance (making investors confident the payout is fully earned), a decline in interest rates (lowering leverage costs and boosting asset values), or shareholder-friendly actions by the fund’s board. On that last point, SCD has in the past authorized share buybacks when the discount was wide – notably a 10% repurchase program initiated in 2015 ([4]). That program was utilized at an average price of ~$12.22 ([4]) (during a period of steep discounts), helping support the market price. The current board could consider such steps again if the discount stays in double digits for long. However, with the recent focus on growing the fund (the rights issue), management may be less inclined to shrink it via buybacks in the near term.
Valuation Bottom Line: At around 90 cents on the dollar, SCD offers a high yield at a discounted price, but with the understanding that part of that yield is effectively one’s own capital coming back unless the fund can continue to generate outsized gains. Value-oriented CEF investors might find it attractive at these levels compared to history, but it’s crucial to evaluate the risks (next section) that are being signaled by that discount.
Risks and Red Flags
Market Risk (Equity & Credit): As a multi-asset fund, SCD is exposed to stock market volatility and credit risk in its fixed-income holdings. About 70% of the portfolio is in equities (common stocks, MLPs, REITs) ([3]) – these can decline with broad market downturns or sector-specific shocks. Many top holdings are in technology and financials (e.g. Marvell Technology ~3.8%, Apple ~2.5% of the portfolio) ([3]), so the fund isn’t a pure “defensive” income play; it takes growth-oriented positions too. On the fixed-income side, SCD likely holds high-yield bonds (to boost income) and possibly foreign or structured debt – those carry default and liquidity risk, especially in a recession or stressed credit environment ([7]). Any deterioration in economic conditions could hurt the fund’s NAV from multiple angles.
Leverage Amplification: The use of leverage magnifies nearly all risks. If the market value of the portfolio falls, the drop in NAV is exacerbated by the loan (since debt remains fixed while assets shrink). A roughly 25% leverage means a 10% asset decline would translate to ~13.3% decline in NAV. In a sharp downturn, the fund could breach asset coverage covenants, potentially forcing asset sales or dividend suspension. While SCD’s credit facility has covenants to prevent excessive leverage, a fast market drop could require quick deleveraging at an inopportune time. The fund itself warns that leveraging will make its NAV more volatile and compound other risks ([6]). Additionally, interest rate risk is two-fold: rising rates not only reduce the market value of bonds in the portfolio, but also increase the cost of the fund’s borrowings, squeezing net income. We’ve seen this play out with the fund’s interest expense jumping in recent periods ([4]). If short-term rates rise further or stay elevated, SCD’s earnings could be pressured, potentially leading to more ROC in distributions or a need to dial back leverage.
Distribution Sustainability: The managed distribution policy, while attractive for income investors, poses a risk if not supported by returns. In years where SCD cannot realize sufficient gains, it will either erode NAV by returning capital or may have to consider a dividend cut. A red flag is that the fund already had significant ROC in some past years (e.g. 2020–2022) ([4]), and its 12-month NAV total return (~4.8%) currently lags the payout rate (9%+) ([2]). This suggests a potential NAV erosion if the situation persists. A dividend reduction, while not immediately signaled, is not off the table in a prolonged weak market – though the managers would likely exhaust other options first (realizing gains, adjusting portfolio) to maintain the policy. Any cut could materially impact the stock price (CEF investors often punish distribution cuts with wider discounts).
Managed Assets & Fees: Another point to watch is the incentive structure. The fund’s advisory fee is 0.85% of managed assets (including leverage) ([4]). This means the manager earns fees on the leveraged portion as well, which can be seen as a conflict: there is a temptation to use leverage or even grow the fund (via new share issuance) to increase fee revenue. The mid-2025 rights offering, for instance, grew assets (and thus fees) but was dilutive to existing shareholders’ NAV. While the offering was done at a moderate discount and with oversubscription (indicating investor appetite) ([3]), shareholders should be wary if the fund repeatedly issues new shares below NAV – a pattern which would suggest a management focus on asset growth over shareholder value. The 2015 buyback authorization indicates the board has at times acted to enhance shareholder value when discounts were large ([4]). It’s a mixed signal: management is willing both to repurchase shares (at deep discount) and to issue shares (via rights) when conditions favor. Active shareholders might keep an eye on this balance and advocate as needed.
Sector-Specific and Other Risks: Because SCD can invest in MLPs up to 25% of assets ([1]), it has some exposure to the energy infrastructure sector. MLPs carry their own risks (commodity price sensitivity, regulatory risk, and the potential for distribution cuts at the underlying MLP level). The fund’s MLP investments also pass through return of capital to SCD (as MLP distributions often are tax-deferred ROC), which SCD in turn passes to shareholders ([4]) – this accounting nuance can make income look lower and ROC higher, even if economically those MLP payouts are supporting the fund’s distribution. Additionally, SCD’s ability to invest abroad (it has a sub-advisor for non-U.S. securities ([4]) ([4])) introduces currency and geopolitical risks if the fund holds non-USD assets. Finally, liquidity risk in parts of the portfolio (e.g. high-yield bonds or less liquid equities) could impair NAV if the fund needs to sell into a weak market, especially under a leverage unwind scenario.
In summary, SCD carries a higher risk profile than a plain-vanilla equity fund or an investment-grade bond fund because of its leveraged, multi-asset strategy. The key red flags to monitor are: persistent NAV erosion (signaling an overdistribution), widening discount (market caution), and any signs of future dilutive actions. Thus far, the fund has managed through volatility with active management and tactical moves, but investors should remain vigilant.
Valuation Upside and Open Questions
Given the above risks, why might an investor still be hopeful on SCD (and what sparks hope now)? A few points and open questions stand out:
– Improving Market Conditions? The title’s reference to “New Data Sparks Hope at ASH Annual Meeting” highlights breakthroughs (in the biomedical context) – by analogy, one could ask: Is there “new data” for SCD (the fund) that sparks hope? For instance, recent gene therapy successes for Sickle Cell Disease (SCD) were reported at the ASH meeting, boosting biotech sentiment ([8]). While LMP Capital & Income Fund is not a direct biotech play, it does hold broad equity exposure. Any robust market rally (whether driven by biotech breakthroughs, tech earnings, or falling interest rates) would lift SCD’s NAV and make its distribution more secure. Open question: Will 2024–2025 deliver a market environment that allows SCD’s total return to meet or exceed its 9% distribution? If equity markets perform well (as they have in parts of 2023), SCD’s strategy could thrive and even allow for NAV growth while paying shareholders handsomely.
– Interest Rate Trajectory: With SCD’s fate tied partly to rates, another question is where interest costs and bond yields head from here. If the Federal Reserve has peaked rates and we see a decline in short-term rates in late 2024 or 2025, SCD would benefit via lower leverage expense and likely higher bond prices. Conversely, if rates stay “higher for longer,” the fund might reallocate more to high-yield bonds now available at 8-9% yields to bolster NII. Open question: Can SCD reposition its fixed-income sleeve to take advantage of today’s yield opportunities without taking undue risk, thus improving NII coverage? The semi-annual report shows relatively modest portfolio turnover (17% in six months) ([4]), so any allocation shifts will be incremental.
– Discount Catalysts: With the discount near 10%, there’s an implicit upside if it narrows. Will management take steps to narrow the discount? The prior buyback program (2015) sets a precedent that the board doesn’t want an excessively wide discount. There’s no current announced buyback, but shareholders might pressure for one if the discount persists. Additionally, larger asset managers sometimes merge or liquidate underperforming funds – not on the table yet for SCD, but an eventual possibility if performance doesn’t justify the expenses. Keep an eye on activist investors: Open question: Could an activist emerge to push for measures (tender offer, managed wind-down, or merger) if SCD’s discount remains in double digits? While no specific activist involvement is public, the CEF space has seen more of this in recent years.
– Rights Offering Overhang: Now that the 2025 rights issue is done, what is management’s plan for the new capital? The offering was pitched as a way to leverage opportunities and potentially increase distribution stability (often, more assets can help maintain payout by scaling into new investments). Open question: Has the new capital been deployed in a way that will materially boost future NII or NAV growth? Shareholders will look for evidence that the ~$87M raised is accretive – e.g., higher income or improved diversification – rather than just resulting in a larger (but not better-performing) fund. The next annual report’s breakdown of NII and gains will be telling.
– Portfolio Positioning: Lastly, the evolving portfolio mix is an open question. The fund’s objective gives managers wide latitude, from large-cap stocks to REITs, MLPs, and bonds ([1]). As economic “new data” comes in (e.g., signs of inflation cooling, corporate earnings trends, etc.), how will SCD rotate? Will it emphasize higher-quality bonds now yielding more, or double-down on equities if a bull market resumes? The ability of ClearBridge (equity sub-advisor) and Western Asset (fixed-income sub-advisor) to dynamically allocate is crucial. An investor might ask: What is the current tilt of SCD’s portfolio, and do we agree with that stance? As of the latest fact sheet, the fund had significant tech and financial exposure on the equity side and some high-yield on the bond side ([3]) ([4]) – a somewhat pro-cyclical stance. If one is hopeful about the economy and markets (and perhaps biotechnology breakthroughs fueling risk-on sentiment), SCD’s positioning could pay off. If one is defensive, they might question whether the fund should de-risk.
In conclusion, SCD offers a high yield and diversified exposure with active management, but it comes with the trade-offs of leverage and a not-fully-covered distribution. New developments – be it in medicine, macroeconomics, or market trends – will influence SCD’s performance going forward. The hope sparked by new data (to borrow the ASH meeting phrase) is that favorable market “data” will allow the fund to continue delivering on its payout without eroding value. Investors should continuously monitor the fund’s earnings vs. distribution, its discount level, and management’s actions. While the 9% yield is enticing in today’s income-hungry climate, diligent attention to the underlying sources of that yield is warranted. SCD’s story is ultimately one of balancing income and capital – and whether that balance can be maintained in the shareholders’ favor.
Sources:
– LMP Capital and Income Fund Inc. profile and strategy ([1]) ([1]) – Franklin Templeton (ClearBridge) Fund information on distribution rates and recent rights offering ([3]) ([3]) ([3]) – Semi-Annual Report May 2024 – details on leverage, interest expense, and distribution composition ([4]) ([4]) ([4]) – CEFConnect data – pricing, discount/premium history, and distribution details ([2]) ([2]) ([2]) – MarketScreener/Business Wire – Section 19(a) notices showing distribution source breakdown (e.g. ~86% from long-term gains) ([5]) – Reuters – context on sickle cell (SCD) gene therapy success at ASH, illustrating broader market optimism catalysts ([8]) – Fund annual and semiannual reports – historical financial highlights and prior corporate actions (buyback authorization, etc.) ([4]) ([4]).
Sources
- https://marketscreener.com/quote/stock/LMP-CAPITAL-AND-INCOME-FU-14333/
- https://cefconnect.com/Details/SummaryPrint.aspx?Ticker=SCD
- https://franklintempleton.com/clearbridge/closed-end-funds/90324/SINGLCLASS/lmp-capital-and-income-fund-inc/SCD
- https://sec.gov/Archives/edgar/data/1270131/000113322824007112/lcaifi-efp8235_ncsrs.htm
- https://marketscreener.com/quote/stock/LMP-CAPITAL-AND-INCOME-FU-14333/news/LMP-Capital-and-Income-Fund-Inc-SCD-or-the-Fund-CUSIP-50208A102-Announces-Notification-of-47974613/
- https://marketscreener.com/quote/stock/LMP-CAPITAL-AND-INCOME-FU-14333/news/LMP-Capital-and-Income-Fund-Factsheet-LMP-Capital-and-Income-Fund-Inc-45108987/
- https://sec.gov/Archives/edgar/data/1270131/000119312525068774/d901662d424b5.htm
- https://reuters.com/business/healthcare-pharmaceuticals/vertexs-gene-therapy-shows-promise-younger-children-with-blood-disorders-2025-12-06/
For informational purposes only; not investment advice.